Compass Therapeutics Sees Unusually High Options Volume (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of unusually large options trading activity on Tuesday. Traders purchased 7,069 call options on the company. This represents an increase of approximately 411% compared to the typical volume of 1,383 call options.

Compass Therapeutics Stock Up 3.7%

Shares of NASDAQ:CMPX opened at $5.29 on Wednesday. The firm has a market capitalization of $952.68 million, a PE ratio of -12.30 and a beta of 1.48. The company has a 50-day moving average price of $5.87 and a two-hundred day moving average price of $5.06. Compass Therapeutics has a twelve month low of $1.33 and a twelve month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

A number of large investors have recently made changes to their positions in CMPX. Russell Investments Group Ltd. raised its stake in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. Creative Planning purchased a new stake in Compass Therapeutics during the 2nd quarter worth about $30,000. Flagship Harbor Advisors LLC bought a new position in Compass Therapeutics in the 4th quarter worth about $32,000. Strs Ohio bought a new position in Compass Therapeutics in the 1st quarter worth about $34,000. Finally, Apollon Wealth Management LLC purchased a new position in Compass Therapeutics during the 3rd quarter valued at about $35,000. 68.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on CMPX. Canaccord Genuity Group set a $13.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, February 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $9.00 price target on shares of Compass Therapeutics in a report on Thursday, March 5th. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a research note on Thursday, March 5th. Finally, Wall Street Zen raised Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $13.45.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.